Braxia Scientific Corp. (BRAXF)
USD 0.0
(-9.09%)
USD 0.0
(-9.09%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.7 Million CAD | 3.8% |
| 2022 | -7.13 Million CAD | 32.98% |
| 2021 | -10.64 Million CAD | -6148.63% |
| 2020 | -170.4 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -733.31 Thousand CAD | 65.12% |
| 2024 Q3 | -783.35 Thousand CAD | -365.15% |
| 2024 Q2 | -186.31 Thousand CAD | 76.6% |
| 2023 Q1 | -917.13 Thousand CAD | 50.49% |
| 2023 FY | - CAD | 3.8% |
| 2023 Q4 | -2.12 Million CAD | 4.62% |
| 2023 Q3 | -2.23 Million CAD | -40.1% |
| 2023 Q2 | -1.59 Million CAD | -73.56% |
| 2022 FY | - CAD | 32.98% |
| 2022 Q2 | -1.71 Million CAD | -59.95% |
| 2022 Q1 | -1.06 Million CAD | 51.62% |
| 2022 Q3 | -2.5 Million CAD | -46.4% |
| 2022 Q4 | -1.85 Million CAD | 26.01% |
| 2021 FY | - CAD | -6148.63% |
| 2021 Q2 | -2.04 Million CAD | 58.76% |
| 2021 Q1 | -4.96 Million CAD | -78.58% |
| 2021 Q3 | -1.5 Million CAD | 26.63% |
| 2021 Q4 | -2.21 Million CAD | -47.14% |
| 2020 Q4 | -2.77 Million CAD | -1792.36% |
| 2020 FY | - CAD | 0.0% |
| 2020 Q3 | -146.9 Thousand CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 82.116% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -114.27% |
| SQZ Biotechnologies Company | -64.14 Million USD | 80.194% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 26.863% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 113.509% |
| Mesoblast Limited | -62.38 Million USD | 79.638% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -727.048% |
| Genus plc | 73.7 Million USD | 117.237% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -92.147% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -258.158% |
| Marizyme, Inc. | -34.28 Million USD | 62.942% |
| ContraFect Corporation | -64.99 Million USD | 80.455% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -44.823% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -180.674% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -806.248% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -380.397% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -446.68% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2352.265% |
| Accustem Sciences Inc. | -3.74 Million USD | -239.093% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 73.658% |
| EV Biologics, Inc. | -1.26 Million USD | -902.568% |
| Q BioMed Inc. | -617.62 Thousand USD | -1956.879% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 455.651% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1908.814% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -456.092% |
| Biomind Labs Inc. | -1.03 Million USD | -1127.961% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 228.621% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -77.397% |
| Skye Bioscience, Inc. | -13.54 Million USD | 6.228% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -754.092% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -50715.444% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -227.055% |
| IMV Inc. | -35.52 Million USD | 64.238% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 19.949% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -407.756% |
| GB Sciences, Inc. | -1.41 Million USD | -794.711% |
| Alpha Cognition Inc. | -9.7 Million USD | -30.892% |
| HST Global, Inc. | -5303.00 USD | -239459.891% |
| CSL Limited | 4.78 Billion USD | 100.265% |
| Halberd Corporation | -74.27 Thousand USD | -17002.897% |
| Enzolytics Inc. | -2.12 Million USD | -498.666% |
| Resverlogix Corp. | -11.74 Million USD | -8.192% |
| Affymax, Inc. | -14.29 Million USD | 11.131% |
| SYBLEU INC | -141.57 Thousand USD | -8873.491% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -314.75% |
| argenx SE | -216.02 Million USD | 94.119% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 77.044% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1143.867% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -747.542% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3453.322% |
| AVAX Technologies, Inc. | -6.11 Million USD | -107.829% |
| Zenith Capital Corp. | -8.6 Million USD | -47.616% |
| Genscript Biotech Corporation | -248.71 Million USD | 94.892% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -72822.685% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -419.275% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -7117.104% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 67.949% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -339.226% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1114.156% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 189033.09% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -625.935% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -561.346% |
| BioStem Technologies, Inc. | -7.55 Million USD | -68.182% |
| ONE Bio Corp. | 13.61 Million USD | 193.321% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -6915.297% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -517.592% |
| Agentix Corp. | -1.37 Million USD | -826.102% |
| LadRx Corporation | 412.28 Thousand USD | 3181.345% |
| Cell Source, Inc. | -4.27 Million USD | -197.338% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3359.459% |
| Regen BioPharma, Inc. | 1.46 Million USD | 966.592% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1255.875% |
| NovAccess Global Inc. | -1.03 Million USD | -1127.667% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 243.485% |
| Itoco Inc. | -1.86 Million USD | -579.716% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -3246.468% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1038.339% |
| Kadimastem Ltd | -2.62 Million USD | -384.071% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -5212.089% |
| CytoDyn Inc. | -18.02 Million USD | 29.537% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -15974.936% |
| Mobile Lads Corp. | -2.24 Million USD | -466.843% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -103783.073% |
| Qrons Inc. | -40.08 Thousand USD | -31595.469% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2515.696% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2508.621% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1235.842% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1096.209% |
| International Stem Cell Corporation | 202 Thousand USD | 6389.04% |
| Bioxytran, Inc. | -3.82 Million USD | -232.549% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -24033.475% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -416.012% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 64.583% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -28130.802% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -363.983% |
| Neutra Corp. | -181.24 Thousand USD | -6909.143% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 36.982% |
| PureTech Health plc | -11.62 Million USD | -9.262% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 36.977% |
| IXICO plc | -707 Thousand USD | -1696.869% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -65.307% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 73.723% |
| CSL Limited | 4.73 Billion USD | 100.268% |
| Cellectis S.A. | -92.63 Million USD | 86.286% |